Introduction to mild-to-moderate psoriasis

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

The treatment of psoriasis has changed dramatically over the past five years with the emergence of biologic therapies primarily for moderate-to-severe disease. Nevertheless, topical therapy remains the most commonly prescribed treatment for psoriasis. The vast majority of patients have mild-to-moderate disease and are therefore reluctant to use systemic treatments. Surveys performed by the National Psoriasis Foundation (NPF) show that a large proportion of patients with disease affecting more than 10% of their body surface area (BSA) are treated with topical therapy alone. Moreover, the vast majority of patients treated with systemic agents including biologics require treatment with topical prescriptions as well. Successful therapy for biologic agents is measured by the Psoriasis Area and Severity Index (PASI) 75, i.e., 75% improvement in this measure of psoriasis severity. How is the other 25% treated? Most often, it is treated with topical therapy and occasionally with phototherapy.

Original languageEnglish
Title of host publicationMild-to-Moderate Psoriasis, Second Edition
PublisherCRC Press
Pages1-3
Number of pages3
ISBN (Electronic)9781420088618
ISBN (Print)9781420088601
StatePublished - 1 Jan 2008

Fingerprint

Dive into the research topics of 'Introduction to mild-to-moderate psoriasis'. Together they form a unique fingerprint.

Cite this